• Explore /
  • Poster
  • / A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with <em>KRAS</em> G12C mutant advanced solid tumors.

A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.

Abstract Poster

Authors

null

Iwona A. Lugowska

Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Iwona A. Lugowska , Carlos Rojas , Anastasios Stathis , Susanne Weindler , Abhijit Pal , Eduardo Castanon Alvarez , Jacek Mackiewicz , Marcelo Garrido , Mehmet Ali Nahit Sendur , Nehal J. Lakhani , Sophia Frentzas , Rafal Dziadziuszko , Adrian G. Sacher , Kazushige Wakuda , Terufumi Kato , Ruth Perets , Omar Orlando Castillo Fernandez , Thomas Jemielita , Yewon Choi , Rosalyn A. Juergens

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05067283

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS232)

DOI

10.1200/JCO.2024.42.3_suppl.TPS232

Abstract #

TPS232

Poster Bd #

N20

Abstract Disclosures

Similar Posters

First Author: Suzanne Fields Jones

First Author: Eelke Gort

First Author: Susanna Varkey Ulahannan

First Author: Jordi Rodon Ahnert